DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5223是一项对78名HIV-1感染者进行的非随机前瞻性评估，旨在确定LPV在男性和女性中的药代动力学(PK)。受试者将按性别、种族和民族进行分层。他们将在服用早晨剂量的洛匹那韦/利托那韦(LPV/RTV)之前和12小时后获得的血浆样本上进行药代动力学评估。这项研究将使我们开始更好地了解抗逆转录病毒药物在女性中的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5223 is a non-randomized prospective evaluation of78 HIV-1- infected subjects designed to determine the pharmacokinetics (PK) of LPV in men and women. Subjects will be stratified by sex, race and ethnicity. They will undergo pharmacokinetic evaluations on plasma samples obtained prior to and up to 12 hours after the administration of the morning dose of lopinavir/ritonavir (LPV/RTV). This study will allow us to begin to have a better understanding of the safety and efficacy of antiretroviral agents among women.